Catalyst
Slingshot members are tracking this event:
Lilly (LLY) Announces Positive Phase 3 SPIRIT-P1 Data Evaluating Ixekizumab in Patients With Psoriatic Arthritis
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 08, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Ixekizumab, Psoriatic Arthritis, Spirit-p1
